Axinn Team Prevails for Alvogen in Suboxone Antitrust Litigation
August 26, 2020
In another victory on behalf of Axinn’s client Alvogen, a district court affirmed a previous court ruling that both Alvogen and Dr. Reddy’s Laboratories can move forward with antitrust counterclaims against Indivior. The counterclaims arise from a dispute over generic versions of Suboxone, Indivior’s opioid addiction treatment. The Axinn team included Matt Becker and Ted Mathias.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
Axinn Antitrust Insight: HSR Overhaul: Out with the New, In with the Old
Axinn Viewpoints
Antitrust
The DOJ's Whistleblower Program and Leniency
Axinn Viewpoints
Antitrust
Squires Again Broadens Discretion for Post-Grant Proceedings
Axinn Viewpoints
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity
Axinn Viewpoints
Intellectual Property
Mother, May I? The Use of Prior Approval Requirements in Merger Settlements
Podcast
Antitrust
The Curtain Rises Again on FTC Act Section 5
Axinn Viewpoints

